Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FIBRILAÇÃO ATRIAL, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H. et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, v. 24, n. 3, p. 513-525, 2022Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2381. Acesso em: 16 out. 2024.APA
Butt, J. H., Docherty, K. F., Jhund, P. S., Boer, R. A., Bohm, M., Desai, A. S., et al. (2022). Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, 24( 3), 513-525. doi:10.1002/ejhf.2381NLM
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 out. 16 ] Available from: https://doi.org/10.1002/ejhf.2381Vancouver
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 out. 16 ] Available from: https://doi.org/10.1002/ejhf.2381